Two Sigma Investments LP Increases Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Two Sigma Investments LP boosted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 56.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,328,553 shares of the biotechnology company's stock after buying an additional 478,889 shares during the quarter. Two Sigma Investments LP owned approximately 0.47% of Exelixis worth $44,241,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Exelixis by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company's stock valued at $979,994,000 after acquiring an additional 121,750 shares during the last quarter. LSV Asset Management raised its holdings in Exelixis by 0.8% in the 4th quarter. LSV Asset Management now owns 8,169,847 shares of the biotechnology company's stock valued at $272,056,000 after acquiring an additional 67,470 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its holdings in Exelixis by 10.2% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company's stock valued at $254,110,000 after acquiring an additional 708,312 shares during the last quarter. Invesco Ltd. raised its holdings in Exelixis by 308.1% in the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock valued at $132,376,000 after acquiring an additional 3,001,204 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in Exelixis by 25.7% in the 4th quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company's stock valued at $132,101,000 after acquiring an additional 810,857 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on EXEL. Stifel Nicolaus raised their price target on shares of Exelixis from $36.00 to $38.00 and gave the stock a "hold" rating in a report on Wednesday, May 14th. Guggenheim set a $45.00 price target on shares of Exelixis and gave the stock a "buy" rating in a report on Thursday, May 15th. Citigroup increased their price objective on shares of Exelixis from $45.00 to $56.00 and gave the stock a "buy" rating in a research report on Thursday, May 15th. Truist Financial increased their price objective on shares of Exelixis from $42.00 to $43.00 and gave the stock a "buy" rating in a research report on Monday, January 27th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $41.00 price objective on shares of Exelixis in a research report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and twelve have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $38.94.

Insider Buying and Selling at Exelixis

In other news, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the sale, the executive vice president now directly owns 303,310 shares of the company's stock, valued at approximately $11,216,403.80. The trade was a 14.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Christopher J. Senner sold 29,314 shares of Exelixis stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the sale, the chief financial officer now directly owns 779,607 shares of the company's stock, valued at approximately $28,174,996.98. This trade represents a 3.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 559,873 shares of company stock valued at $24,646,347 in the last 90 days. Company insiders own 2.82% of the company's stock.

Exelixis Stock Down 1.1%

EXEL stock traded down $0.47 during midday trading on Friday, hitting $42.39. The company's stock had a trading volume of 2,939,995 shares, compared to its average volume of 2,300,007. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $48.85. The firm has a market capitalization of $11.56 billion, a P/E ratio of 23.95, a PEG ratio of 1.13 and a beta of 0.25. The firm has a 50-day simple moving average of $37.91 and a 200-day simple moving average of $36.14.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.